DCPD is currently under review in the EU as part of an ongoing ECHA Community Rolling Action Plan (CoRAP) procedure linked to its REACH registration (France, 2015). The substance was also evaluated as part of the French National Strategy on Endocrine Disruptors (SNPE, 2014), whereby recently published information suggests that ANSES (the French Agency for Food, Environmental and Occupational Health & Safety) is not considering the substance as a potential endocrine disruptor (ED).

In this context, the LOSG (Lower Olefins Sector Group) Toxicology working group formed an ad hoc expert group to evaluate available toxicological and mechanistic information on DCPD, in view of establishing or excluding an ED-related mechanism for the observed developmental effects.
The expert group reviewed the available scientific information, and the existing experimental data was complemented with structure ctivity modelling using ECHA-recommended (Q)SAR tools. Overall, no indication of endocrine-mediated adversity was found. Hence, the available evidence supports the conclusion that DCPD does not cause developmental toxicity via an endocrine mode of action. This work is published in a peer-reviewed journal.
The full open-access article can be found via this link.